Recently, Runke Bioengineering’s central laboratory successfully passed the review of the China National Accreditation Service for Conformity Assessment (CNAS) and officially obtained the CNAS laboratory accreditation certificate.

This CNAS accreditation signifies that Runke Bioengineering has reached a higher level of national recognition in the testing of products such as DHA and ARA, as well as in laboratory management. It enables the company to fully align its product quality with international standards, laying a more solid technical foundation for the company to continuously provide high-quality products.

CNAS, established and authorized by the Certification and Accreditation Administration of the People’s Republic of China, is the only national conformity assessment accreditation body legally established in our country.

Currently, CNAS has achieved multilateral mutual recognition with international accreditation organizations such as the International Laboratory Accreditation Cooperation (ILAC) and the Asia-Pacific Laboratory Accreditation Cooperation (APLAC).

In the future, the testing results of Runke Bioengineering’s DHA, ARA, and other products will be recognized by accreditation bodies in 89 other countries and regions that have signed mutual recognition agreements with CNAS, achieving international mutual recognition of testing results and providing strong quality assurance for entering the global market. Guangdong Runke Bioengineering Co., Ltd. (hereinafter referred to as “Runke Bioengineering”) was founded in Shantou City, Guangdong Province in 2000. It is a national high-tech enterprise that applies modern bioengineering technology to research, develop and produce human health products derived from microalgae.

As the first company in China and the second globally to achieve large-scale production of microalgae DHA, Runke Bioengineering holds the number one market share in the algal oil DHA field in China.

The company boasts a research and development team led by internationally renowned microalgae technology experts, four provincial and municipal-level R&D centers, a corporate microalgae technology R&D platform, a well-equipped pilot plant, and a GMP production base meeting 100,000-level standards. This enables a closed-loop production chain encompassing “algae strain selection – raw material R&D – end-product manufacturing – market application.”

Currently, Runke’s DHA, ARA, and other products are widely used in infant formula, dairy products, health supplements, and food, among other fields. The company is committed to providing high-quality health products and customized solutions to global customers, with a mission to continuously improve the quality of human life and offer high-quality health products to the market.

*The CNAS information on this page is sourced from the China National Accreditation Service for Conformity Assessment’s “Baidu Encyclopedia” entry. Please read rationally.